A double-blind, double-dummy, randomized, placebo-controlled crossover phase I study assessing pharmacokinetics and pharmacodynamics of two different SMC021 [salmon calcitonin] 0.8 mg variants and the effect of timing of drug intake in healthy postmenopausal women
Phase of Trial: Phase I
Latest Information Update: 20 Feb 2009
At a glance
- Drugs Calcitonin (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 20 Feb 2009 Results have been published, according to an Emisphere technologies media release.
- 04 Jan 2007 New trial record.